Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update

NEXT STORY
Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
PREV STORY
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products

Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and ...

author_avatar
NASDAQ Market News

Global Needle-Free Drug Delivery Devices Market is Expected to Reach USD 19.35 Billion by 2025 : Fior Markets

author_avatar
NASDAQ Market News

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indications

author_avatar
NASDAQ Market News